Impact Biomedical (IBO) Non-Current Assets (2022 - 2026)
Impact Biomedical's (IBO) quarterly Non-Current Assets came in at $16.7 million in Q1 2026, down 6.49% YoY from $17.9 million in Q1 2025, and down 1.68% on a QoQ basis from $17.0 million in Q4 2025.
Impact Biomedical (IBO) Non-Current Assets (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Non-Current Assets data on file, last reported at $16.7 million in Q1 2026.
- Quarterly Non-Current Assets fell 6.49% year-over-year to $16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.6 million (down 44.27% YoY) and the FY2025 annual result came in at $17.0 million, down 4.75% from the prior year.
- Non-Current Assets slipped to $16.7 million in Q1 2026, from $17.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $46.4 million in Q4 2022 to a low of $16.7 million in Q1 2026.
- A 5-year average of $32.0 million and a median of $43.5 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets retreated 2.38% — and 2025, when it slumped 60.27%.
- Tracing IBO's Non-Current Assets over 5 years: stood at $46.4 million in 2022, then fell by 4.47% to $44.3 million in 2023, then plunged by 59.73% to $17.8 million in 2024, then fell by 4.75% to $17.0 million in 2025, then decreased by 1.68% to $16.7 million in 2026.
- The last three Non-Current Assets figures came in at $16.7 million (Q1 2026), $17.0 million (Q4 2025), and $17.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 16.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.43 Mn |
| Mar 31, 2026 | 16.71 Mn |
| Dec 31, 2025 | 16.99 Mn |
| Sep 30, 2025 | 17.29 Mn |
| Jun 30, 2025 | 17.58 Mn |
| Mar 31, 2025 | 17.87 Mn |
| Dec 31, 2024 | 17.84 Mn |
| Sep 30, 2024 | 43.52 Mn |
| Jun 30, 2024 | 43.81 Mn |
| Mar 31, 2024 | 44.02 Mn |
| Dec 31, 2023 | 44.30 Mn |
| Sep 30, 2023 | 44.58 Mn |
| Jun 30, 2023 | 45.64 Mn |
| Dec 31, 2022 | 46.38 Mn |